Head-To-Head Contrast: Nabriva Therapeutics (NASDAQ:NBRV) & AngioSoma (OTCMKTS:SOAN)

Insider & Institutional Ownership

0.0% of AngioSoma shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares AngioSoma and Nabriva Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A
Nabriva Therapeutics	$35.59 million	0.00	-$57.19 million	($19.20)	N/A

AngioSoma has higher earnings, but lower revenue than Nabriva Therapeutics.

Profitability

This table compares AngioSoma and Nabriva Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioSoma	N/A	N/A	-1,245.34%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Volatility and Risk

AngioSoma has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Summary

Nabriva Therapeutics beats AngioSoma on 5 of the 8 factors compared between the two stocks.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.